Cargando…

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

INTRODUCTION: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Epaillard, Nicolas, Parent, Pauline, Loriot, Yohann, Lavaud, Pernelle, Vera-Cea, E-B., Martinez-Chanza, Nieves, Rodriguez-Vida, Alejo, Dumont, Clement, Lozano, Rebeca, Llácer, Casilda, Ratta, Raffaele, Oudard, Stephane, Thibault, Constance, Auclin, Edouard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173179/ https://www.ncbi.nlm.nih.gov/pubmed/34094973 http://dx.doi.org/10.3389/fonc.2021.671969

Ejemplares similares

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
por: Parent, Pauline, et al.
Publicado: (2023)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Lymphadenectomy for Upper Tract Urothelial Carcinoma: A Systematic Review
por: Duquesne, Igor, et al.
Publicado: (2019)

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
por: Lavaud, Pernelle, et al.
Publicado: (2014)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
por: Thouvenin, Jonathan, et al.
Publicado: (2021)

Outcomes in elderly patients admitted to the intensive care unit with solid tumors
por: Auclin, Edouard, et al.
Publicado: (2017)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer
por: Nassif, Elise F., et al.
Publicado: (2021)

Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
por: Vano, Yann-Alexandre, et al.
Publicado: (2018)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?
por: Lebacle, Cedric, et al.
Publicado: (2021)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
por: Nassif, Elise F., et al.
Publicado: (2021)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
por: Martinez Chanza, Nieves, et al.
Publicado: (2021)

Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study
por: Dang, Elodie, et al.
Publicado: (2022)

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study
por: Rezazadeh Kalebasty, Arash, et al.
Publicado: (2022)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
por: Xiao, Yuanyuan, et al.
Publicado: (2014)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic
por: Lenfant, Louis, et al.
Publicado: (2020)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
por: Laé, M., et al.
Publicado: (2010)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee
por: Masson-Lecomte, Alexandra, et al.
Publicado: (2022)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4dhk0d1mb2603b7i9egu9qissg